WGI-0301

· Zhejiang Haichang Biotech Co., Ltd.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for WGI-0301, covering 2026-03-19 to 2026-04-20. Get the full timeline:

Most recent: Clinical Trial Update: Phase 2 Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC [Phase 1, Phase 2]